MedTrace Logo

Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)

NCT04343248 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 190

Last updated 2024-07-08

Study results available
· View outcomes & findings →

Summary

Trial to evaluate the efficacy and safety of NTZ for post-exposure prophylaxis of COVID-19 and other VRIs in elderly LTCF residents.

Conditions

Interventions

DRUG

Nitazoxanide

Nitazoxanide 600 mg administered orally twice daily for six weeks

DRUG

Placebo

Placebo administered orally twice daily for six weeks

DIETARY_SUPPLEMENT

Vitamin Super B-Complex

Vitamin Super B-Complex administered orally twice daily to maintain the blind

Sponsors & Collaborators

  • Romark Laboratories L.C.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-12
Primary Completion
2021-02-01
Completion
2021-02-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04343248 on ClinicalTrials.gov